Impacts of Cytosolic Phospholipase A2, 15-prostaglandin Dehydrogenase, and Cyclooxygenase-2 Expressions on Tumor Progression in Colorectal Cancer

Overview

Journal Yonsei Med J

Specialty General Medicine

Date 2010 Jul 17

PMID 20635443

Citations 17

Authors

Sung Chul Lim

Hoon Cho

Tae Bum Lee

Cheol Hee Choi

Young Don Min

Sung Soo Kim

Kyung Jong Kim

Affiliations

Soon will be listed here.

Abstract

Purpose: In addition to cyclooxygenase-2 (COX-2) which is related to prostaglandin E2 synthesis, other enzymes such as cytosolic phospholipase A2 (cPLA2), microsomal prostaglandin E2 synthase-1 (mPGES-1), and 15-prostaglandin dehydrogenase (15-PGDH) have been suggested to be related to carcinogenesis of colorectal cancer (CRC). The aim of this study was to investigate the roles of cPLA2, COX-2, mPGES-1, and 15-PGDH in tumor progression.

Materials And Methods: cPLA2, COX-2, mPGES-1, 15-PGDH, and vascular endothelial growth factor (VEGF) expressions were immunohistochemically examined in 89 CRC, and their expressions were compared with each other or clinicopathologic parameters as well as VEGF as tumor progression parameters.

Results: cPLA2 was expressed in 54.5%, COX-2 in 80.5%, mPGES-1 in 96.4%, 15-PGDH in 46.1%, and VEGF in 65.9%. The expression of cPLA2 correlated with VEGF expression. COX-2 expression was correlated with the depth of invasion, tumor stage, cPLA2, and VEGF expressions. Moreover, VEGF revealed the highest expression in the tissues positive for both cPLA2 and COX-2. Furthermore, 15-PGDH expression was inversely correlated with VEGF expression.

Conclusion: The present study demonstrates that cPLA2 and mPGES-1, in addition to COX-2, are constitutively overexpressed, and that 15-PGDH might be attenuated in colorectal cancer. Furthermore, cPLA2 and 15-PGDH as well as COX-2 could have an important role in tumor progression.

Citing Articles

Non-Targeted Serum Lipidomics Analysis and Potential Biomarkers of Laryngeal Cancer Based on UHPLC-QTOF-MS.

Wang H, Luo Y, Chen H, Hou H, Hu Q, Ji M Metabolites. 2022; 12(11).

PMID: 36355170 PMC: 9695307. DOI: 10.3390/metabo12111087.

Upregulation of prostaglandin E2 by inducible microsomal prostaglandin E synthase-1 in colon cancer.

Kim Y, Kim K Ann Coloproctol. 2021; 38(2):153-159.

PMID: 34465013 PMC: 9021850. DOI: 10.3393/ac.2021.00374.0053.

Mechanism of Apoptosis Induced by Curcumin in Colorectal Cancer.

Ismail N, Othman I, Abas F, Lajis N, Naidu R Int J Mol Sci. 2019; 20(10).

PMID: 31108984 PMC: 6566943. DOI: 10.3390/ijms20102454.

CD147 and Cyclooxygenase Expression in Feline Oral Squamous Cell Carcinoma.

Nasry W, Wang H, Jones K, Dirksen W, Rosol T, Rodriguez-Lecompte J Vet Sci. 2018; 5(3).

PMID: 30104530 PMC: 6163611. DOI: 10.3390/vetsci5030072.

Nanoliposomal delivery of cytosolic phospholipase A inhibitor arachidonyl trimethyl ketone for melanoma treatment.

Gowda R, Dinavahi S, Iyer S, Banerjee S, Neves R, Pameijer C Nanomedicine. 2018; 14(3):863-873.

PMID: 29317343 PMC: 5899023. DOI: 10.1016/j.nano.2017.12.020.

References

Laye J, Gill J . Phospholipase A2 expression in tumours: a target for therapeutic intervention?. Drug Discov Today. 2003; 8(15):710-6. DOI: 10.1016/s1359-6446(03)02754-5. View

Mehrotra S, Morimiya A, Agarwal B, Konger R, Badve S . Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy. J Pathol. 2005; 208(3):356-63. DOI: 10.1002/path.1907. View

Bonventre J, Huang Z, Taheri M, OLeary E, Li E, Moskowitz M . Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature. 1997; 390(6660):622-5. DOI: 10.1038/37635. View

Zhang H, Sun X . Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol. 2002; 97(4):1037-41. DOI: 10.1111/j.1572-0241.2002.05625.x. View

Soumaoro L, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K . Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004; 10(24):8465-71. DOI: 10.1158/1078-0432.CCR-04-0653. View

Balsinde J, Balboa M, Insel P, Dennis E . Regulation and inhibition of phospholipase A2. Annu Rev Pharmacol Toxicol. 1999; 39:175-89. DOI: 10.1146/annurev.pharmtox.39.1.175. View

Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I . Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem. 2000; 275(42):32775-82. DOI: 10.1074/jbc.M003504200. View

Ilsley J, Nakanishi M, Flynn C, Belinsky G, De Guise S, Adib J . Cytoplasmic phospholipase A2 deletion enhances colon tumorigenesis. Cancer Res. 2005; 65(7):2636-43. DOI: 10.1158/0008-5472.CAN-04-3446. View

Lim S, Lee T, Choi C, Ryu S, Min Y, Kim K . Prognostic significance of cyclooxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer. J Surg Oncol. 2007; 97(1):51-6. DOI: 10.1002/jso.20907. View

10.

Ensor C, Tai H . 15-Hydroxyprostaglandin dehydrogenase. J Lipid Mediat Cell Signal. 1995; 12(2-3):313-9. DOI: 10.1016/0929-7855(95)00040-w. View

11.

Panel V, Boelle P, Ayala-Sanmartin J, Jouniaux A, Hamelin R, Masliah J . Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production. Cancer Lett. 2006; 243(2):255-63. DOI: 10.1016/j.canlet.2005.11.045. View

12.

Gee J, Montoya R, Khaled H, Sabichi A, Grossman H . Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol. 2003; 21(4):266-70. DOI: 10.1016/s1078-1439(02)00271-5. View

13.

Takaku K, Sonoshita M, Sasaki N, Uozumi N, Doi Y, Shimizu T . Suppression of intestinal polyposis in Apc(delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene. J Biol Chem. 2000; 275(44):34013-6. DOI: 10.1074/jbc.C000585200. View

14.

Trebino C, Stock J, Gibbons C, Naiman B, Wachtmann T, Umland J . Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci U S A. 2003; 100(15):9044-9. PMC: 166435. DOI: 10.1073/pnas.1332766100. View

15.

Petersen S, Haroske G, Hellmich G, Ludwig K, Petersen C, Eicheler W . COX-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome. Anticancer Res. 2002; 22(2B):1225-30. View

16.

Dong M, Guda K, Nambiar P, Rezaie A, Belinsky G, Lambeau G . Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis. 2003; 24(2):307-15. DOI: 10.1093/carcin/24.2.307. View

17.

van Rees B, Sivula A, Thoren S, Yokozaki H, Jakobsson P, Offerhaus G . Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines. Int J Cancer. 2003; 107(4):551-6. DOI: 10.1002/ijc.11422. View

18.

Backlund M, Mann J, Holla V, Buchanan F, Tai H, Musiek E . 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem. 2004; 280(5):3217-23. PMC: 1847633. DOI: 10.1074/jbc.M411221200. View

19.

Fux R, Schwab M, Thon K, Gleiter C, Fritz P . Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. Clin Cancer Res. 2005; 11(13):4754-60. DOI: 10.1158/1078-0432.CCR-04-2586. View

20.

Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F . Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem. 2000; 275(42):32783-92. DOI: 10.1074/jbc.M003505200. View